Targeting KRAS: Good, But Is It Good Enough?

doi:10.6004/jnccn.2021.0044

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Community

Back to search

Article

Targeting KRAS: Good, But Is It Good Enough?

Journal of the National Comprehensive Cancer Network : JNCCN - 20 Sept 2021

Tempero Margaret

Abstract excerpt

No abstract is available from the source.

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Proto-Oncogene Proteins p21(ras)
Share to Lung Neoplasms
Share to Mutation
Share to Protein Kinase Inhibitors

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Open in PubMed

Identifiers

PMID: 34551387
DOI: 10.6004/jnccn.2021.0044

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 5 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Targeting KRAS: Good, But Is It Good Enough?PMID 34551387Read ↗

Expanding the options for KRAS inhibition.Semantic proximity Read ↗

KRAS: Druggable at Last.Semantic proximity Read ↗

A bright future for KRAS inhibitors.Semantic proximity Read ↗

Targeting KRAS with reversible inhibitors.Semantic proximity Read ↗

Tracing the origins of KRAS oncogene addiction.Semantic proximity Read ↗

"Undruggable KRAS": druggable after all.Semantic proximity Read ↗

Targeting Mutated KRAS Genes to Treat Solid Tumours.Semantic proximity Read ↗

The Effective Targeting of KRASG12C Elusiveness.Semantic proximity Read ↗

Ready, Set, Go: Setting Off on the Mission to Target KRAS in Colorectal Cancer.Semantic proximity Read ↗

Stopping the beating heart of cancer: KRAS reviewed.Semantic proximity Read ↗

Not just gRASping at flaws: finding vulnerabilities to develop novel therapies for treating KRAS mutant cancers.Semantic proximity Read ↗

Targeting mutant KRAS.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.